Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial.
Lui G, Treluyer JM, Fresneau B, Piperno-Neumann S, Gaspar N, Corradini N, Gentet JC, Marec Berard P, Laurence V, Schneider P, Entz-Werle N, Pacquement H, Millot F, Taque S, Freycon C, Lervat C, Le Deley MC, Mahier Ait Oukhatar C, Brugieres L, Le Teuff G, Bouazza N; Sarcoma Group of UNICANCER. Lui G, et al. J Clin Pharmacol. 2018 Dec;58(12):1541-1549. doi: 10.1002/jcph.1252. Epub 2018 May 23. J Clin Pharmacol. 2018. PMID: 29791011 Clinical Trial.
Bone sarcomas: from biology to targeted therapies.
Gaspar N, Di Giannatale A, Geoerger B, Redini F, Corradini N, Enz-Werle N, Tirode F, Marec-Berard P, Gentet JC, Laurence V, Piperno-Neumann S, Oberlin O, Brugieres L. Gaspar N, et al. Sarcoma. 2012;2012:301975. doi: 10.1155/2012/301975. Epub 2012 Nov 27. Sarcoma. 2012. PMID: 23226965 Free PMC article.
The off-label use of targeted therapies in sarcomas: the OUTC'S program.
Eberst L, Cropet C, Le Cesne A, Pautier P, Penel N, Adenis A, Chevreau C, Bay JO, Collard O, Cupissol D, Duffaud F, Gentet JC, Piperno-Neumann S, Marec-Berard P, Bompas E, Thyss A, Chaigneau L, Cassier P, Bertucci F, Blay JY, Ray-Coquard I. Eberst L, et al. BMC Cancer. 2014 Nov 24;14:870. doi: 10.1186/1471-2407-14-870. BMC Cancer. 2014. PMID: 25420707 Free PMC article. Clinical Trial.
Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).
Penel-Page M, Ray-Coquard I, Larcade J, Girodet M, Bouclier L, Rogasik M, Corradini N, Entz-Werle N, Brugieres L, Domont J, Lervat C, Piperno-Neumann S, Pacquement H, Bay JO, Gentet JC, Thyss A, Chaigneau L, Narciso B, Cornille H, Blay JY, Marec-Bérard P. Penel-Page M, et al. BMC Cancer. 2015 Nov 5;15:854. doi: 10.1186/s12885-015-1894-5. BMC Cancer. 2015. PMID: 26541413 Free PMC article.
Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Piperno-Neumann S, Le Deley MC, Rédini F, Pacquement H, Marec-Bérard P, Petit P, Brisse H, Lervat C, Gentet JC, Entz-Werlé N, Italiano A, Corradini N, Bompas E, Penel N, Tabone MD, Gomez-Brouchet A, Guinebretière JM, Mascard E, Gouin F, Chevance A, Bonnet N, Blay JY, Brugières L; Sarcoma Group of UNICANCER; French Society of Pediatric Oncology (SFCE); French Sarcoma Group (GSF-GETO). Piperno-Neumann S, et al. Lancet Oncol. 2016 Aug;17(8):1070-1080. doi: 10.1016/S1470-2045(16)30096-1. Epub 2016 Jun 17. Lancet Oncol. 2016. PMID: 27324280 Clinical Trial.
Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study.
Tabone MD, Brugières L, Piperno-Neumann S, Selva MA, Marec-Bérard P, Pacquement H, Lervat C, Corradini N, Gentet JC, Couderc R, Chevance A, Mahier-Ait Oukhatar C, Entz-Werle N, Blay JY, Le Deley MC. Tabone MD, et al. BMC Cancer. 2017 Jun 15;17(1):419. doi: 10.1186/s12885-017-3409-z. BMC Cancer. 2017. PMID: 28619014 Free PMC article.
CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial.
Gomez-Brouchet A, Illac C, Gilhodes J, Bouvier C, Aubert S, Guinebretiere JM, Marie B, Larousserie F, Entz-Werlé N, de Pinieux G, Filleron T, Minard V, Minville V, Mascard E, Gouin F, Jimenez M, Ledeley MC, Piperno-Neumann S, Brugieres L, Rédini F. Gomez-Brouchet A, et al. Oncoimmunology. 2017 Aug 24;6(9):e1331193. doi: 10.1080/2162402X.2017.1331193. eCollection 2017. Oncoimmunology. 2017. PMID: 28932633 Free PMC article.
Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
Gaspar N, Occean BV, Pacquement H, Bompas E, Bouvier C, Brisse HJ, Castex MP, Cheurfa N, Corradini N, Delaye J, Entz-Werlé N, Gentet JC, Italiano A, Lervat C, Marec-Berard P, Mascard E, Redini F, Saumet L, Schmitt C, Tabone MD, Verite-Goulard C, Le Deley MC, Piperno-Neumann S, Brugieres L; SFCE (Société Française des Cancers de l'Enfant et l'adolescent); GSF-GETO (Groupe Sarcome Français); UNICANCER sarcoma group. Gaspar N, et al. Eur J Cancer. 2018 Jan;88:57-66. doi: 10.1016/j.ejca.2017.09.036. Epub 2017 Nov 28. Eur J Cancer. 2018. PMID: 29190507 Clinical Trial.
202 results